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Prostatic acid phosphatase (PAP) and prostate-specific antigen (PSA) are the mark-
ers of human prostatic gland. However, it is still not completely understood if and
how, steroid hormones and growth factors affect their expression and metabolism in
the respect to the major pathologies of the gland. Appropriate studies were carried out
on histopathologically diagnosed benign prostatic hyperplasia — BPH (n = 42) using
tissue slices and cells derived from them. They were incubated with steroid hormones:
5--dihydrotestosterone (DHT), estradiol (E) and growth factors: epidermal growth
factor (EGF), basic fibroblastic growth factor (bFGF) under culture conditions for up
to 24 hours.
32
P-labelled specific oligonucleotide probes were used to analyze total
RNA isolated from each sample for the presence of PAP and PSA mRNAs.
DHT, E, bFGF, EGF or both DHT + bFGF and DHT + EGF increased PAP and PSA
mRNA levels in a time- and dose-dependent manner. The highest and statistically sig-
nificant increase (P  0.001) for PAP mRNA was observed when DHT + bFGF were
present in the medium while for PSA mRNA if DHT + EGF were added to the medium.
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Slow but constant decrease of PAP and PSA mRNA levels was observed in the ab-
sence of each of these factors in the incubation medium. The results suggest that early
expression of PSA and PAP genes and/or their mRNA stability strongly depend on
DHT while differ in their response to EGF and bFGF.
Benign prostatic hyperplasia (BPH) is very
common in men. Steroid hormones — testos-
terone, its derivative 5--dihydrotestosterone
(DHT) and estradiol (E) as well as growth fac-
tors like epidermal growth factor (EGF),
transforming growth factors alpha and beta
(TGF- and TGF-) and basic fibroblastic
growth factor (bFGF) are among the most im-
portant factors that influence the develop-
ment and function of the prostate gland.
They are also involved in progression of pros-
tatic pathology — BPH and prostate carci-
noma (PC) (Mydlo et al., 1988; Geller, 1990;
Pilarsky et al., 1998). Clinical trials are cur-
rently underway to lower the intracellular
level of DHT and/or estrogens in benign
prostatic hyperplasia (Farnsworth, 1996).
The rational background for such an ap-
proach is the assumption that androgens
(testosterone, DHT) are somehow involved in
the development of BPH, while estradiol and
estrone were found in hyperplastic tissue in a
manifold higher content than in the concen-
tration plasma and skeletal muscle (Krieg et
al., 1997).
The accumulation of bFGF in BPH is due to
the increased synthesis of the factor in the ad-
enomatous tissue itself and to increased syn-
thesis by prostate fibroblasts of the stroma
within the prostate. It is stored in the
extracellular matrix and acts as a mitogen on
the stroma (Guenette & Tenniswood, 1994;
Saez et al., 1999). EGF directly stimulates the
proliferation of both epithelial cells and pros-
tate fibroblast in vitro (Guenette & Tennis-
wood, 1994) and there seems to be a direct re-
lationship between the amount of EGF and an-
drogen in BPH, and the production of EGF re-
ceptor (EGFR) and androgen receptors (AR),
respectively. The close relations between an-
drogens and EGF form a bridge between the
paracrine and endocrine regulation of the
prostate metabolism.
Prostatic acid phosphatase (PAP) is still
used together with prostate-specific antigen
(PSA) — the major marker of the prostate car-
cinoma — and prostate-specific membrane an-
tigen (PMSA) in diagnosis of pathological
changes of prostate tissue (Cooper & Foti,
1974; Robert et al., 1995; Heston, 1996). Clini-
cal studies have shown that the serum level of
PAP and PSA in patients with prostatic carci-
noma decrease in response to endocrine ma-
nipulations by estradiol treatment or orchi-
tectomy. The results obtained from measure-
ments of PAP and PSA serum levels in cancer
patients after endocrine therapy suggest a
similar androgen dependency for the regula-
tion of expression of both these genes (Pamies
& Crawford, 1996). However, it appears that,
in e.g. the LNCaP cell line, the genes of these
two prostate-specific proteins, PAP and PSA
are inversely regulated. The majority of stud-
ies performed to determine the hormonal reg-
ulation of the expression and metabolism of
both these proteins and carried out on estab-
lished prostate cancer cell lines — LNCaP,
DU-145 and PC-3 — brought controversial re-
sults (Janssen et al., 1995). Down-regulation
of PAP by androgens has been reported in the
prostatic carcinoma cell line LNCaP (Henttu
& Vihko, 1992), whereas several studies sup-
port the opposite effect of the hormone (Lin et
al., 1993). Furthermore, the androgen de-
pendency of PSA and human prostate-specific
glandular kallikrein (K2) has been clearly
demonstrated (Murtha et al., 1993). Several
investigations have shown that PSA and K2
gene expression is not strictly restricted to the
prostate. Low levels of PSA have also been de-
tected in the milk of lactating women and in
normal breast cells or breast tumour
(Diamandis & Yu, 1995). On the contrary,
studies using monoclonal antibodies against
PAP have indicated prostate specificity of this
protein, and PAP mRNA expression has never
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been reported outside the prostate (Solin et
al., 1990).
Based both on studies of BPH tissue and on
two androgen-dependent cancer cell lines,
LNCaP and ALVA101, it seems that there is a
complex interaction between EGF and andro-
gen: LNCaP cells possess EGF receptors that
are up-regulated by androgens. The cells se-
crete EGF and a closely related peptide,
TGF-. Their growth is increased by EGF and,
separately, by androgens. In contrast, both
EGF and androgens additively downregulate
secretion of PAP, and the mRNA level of both
PAP and the nuclear ligand-activated andro-
gen receptor. On the other hand, EGF de-
creases but androgen increases secretion of
PSA.
Recently, PAP was suggested as being in-
volved in the regulation of proliferative signal
transduction in prostatic cancer cells (Meng et
al., 2000). The data suggest that expression of
cellular PAP is important to maintain a slow
growth rate and to preserve androgen sensi-
tivity by dephoshorylating ErbB-2 on tyrosine
residues. In the presence of androgen, AR is
activated and leads to stimulation or suppres-
sion of transcription of target genes (Meng et
al., 2000; Peterziel et al., 1999). The alteration
of gene expression through an as yet unidenti-
fied mechanism results in a constitutively ty-
rosine-phosphorylated ErbB-2 protein. The
cellular form of PAP is supposed to function
as a negative regulator of the tyrosine phos-
phorylation signal by dephosphorylating
phosphotyrosine on the c-ErbB-2 protein that
leads to the down-regulation of prostate cell
growth (Lin et al., 1998; Meng & Lin, 1998).
However, relatively little is known regarding
the molecular mechanism of tissue-specific
regulation of the expression of the PAP gene
in prostate cells.
Here, we present results of the studies on
early expression of the two most characteris-
tic prostate proteins, PAP and PSA, at the
level of their mRNAs in response to major ste-
roid hormones (DHT, E) and growth factors
(EGF, bFGF).
MATERIALS AND METHODS
Tissue samples. Samples of prostate tissues
(n = 42) from patients with diagnosed and
histopathologically confirmed hyperplasia (age
72 ± 10) were collected at the time of surgery.
The preparation of tissue slices was done as
previously described (Duliñska et al., 1997).
Isolation of cells. To release epithelial se-
cretory cells characteristic of the synthesis of
PAP and PSA, a part of prostate tissue from
the Surgery Unit was cut with a razor blade
into small slices (1 mm  1 mm  2 mm) and
continuously washed during the procedure
with RPMI 1640 medium (Sigma) to remove
blood and cell debris from the cut surfaces.
Cells were released by overnight treatment of
tissue slices with 0.125% trypsin, 0.05% EDTA
in phosphate-buffered saline (NaCl/Pi), pH
7.4, at 4C (Van Helden et al., 1994). After-
wards slices were washed with the buffer and
left for up to 4–6 weeks in RPMI 1640 with 5%
FCS. During this period the cells released at-
tached to surface and their number was satis-
factory. The slices were removed. The at-
tached cells were cultured up to 72 h.
Enzymatic and histochemical determina-
tion of PAP in isolated cells. Culture me-
dium and cells were analyzed for PAP activity.
The medium was collected and assayed di-
rectly with 20 mM p-nitrophenyl phosphate
(p-NPP) in 50 mM Tris/HCl, pH 7.5. The cell
layer was washed gently with NaCl/Pi and
covered with 200 l of 200 mM p-NPP solution
in 50 mM Tris/HCl, pH 7.5. In both cases
absorbance at 400 nm was measured to assay
PAP (Ostrowski & Tsugita, 1961).
Alternatively, the presence of PAP in the
cells isolated from the tissue was confirmed
histochemically. Cells were fixed on a dish us-
ing 50% acetone in 10 mM acetate buffer, pH,
4.5, for 10 min. Afterwards cells were incu-
bated with napthyl phosphate (2 mg/10 ml)
and hexsazonium pararosanilin (0.8 ml/10
ml) in the acetate buffer at pH 4.5. PAP activ-
ity was visualized as deep-red staining of the
cells (Barka & Andersson, 1962).
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The effect of steroid hormones and
growth factors on the level of PAP and
PSA mRNAs. Weighted (0.1–0.2 g) tissue
slices or cells (105–106) were incubated at
37C in an incubator (5% CO2 and 95% air,
Green Line, ASSAB) for 1, 3, 4, 5 h or over-
night in the RPMI 1640 medium containing
1% L-glutamine, penicillin (100 units/ml),
streptomycin (100 g/ml) and 10% steroid
free fetal calf serum (SF — charcoal-stripped
fetal calf serum (Garcia-Arenas et al., 1995)
without or with: DHT (10–9–10–11 M), E
(10–7–10–9 M), both DHT (10–11 M) and E
(10–7 M), bFGF (10 ng/ml), EGF (10 ng/ml),
both bFGF (10 ng/ml) and DHT (10–11 M),
both EGF (10 ng/ml) and DHT (10–11 M).
Isolation of RNA and Northern blot anal-
ysis. Isolation of total RNA from human pros-
tate tissue slices and Northern blot analysis
were essentially done as previously described
(Duliñska et al., 1997). Usually 0.2 mg of RNA
was obtained from 1 g of prostate tissue. In the
case of RNA preparation from cultured cells
(1.5–2.0  107 cells/sample) they were har-
vested by rubber policeman, pelleted by
centrifugation (1000  g for 6 min), washed
twice with 1  NaCl/Pi, lysed in guanidinium
isothiocyanate solution and homogenized. To-
tal RNA was then purified by centrifugation
through a cesium chloride cushion. Alterna-
tively, total RNA was also isolated from the cul-
tured cells using the TRIzol reagent (Gibco).
The quality of RNA samples was always veri-
fied by spectrophotometric (A260 /A280) and
electrophoretic (1.2% agarose gel) analysis.
Statistical analysis. Statistical compari-
sons among population were performed using
the SAS program for statistical analysis and
verified based on Student’s t-test (Daniels,
1999). Differences were considered signifi-
cant when P < 0.05.
RESULTS
Four deoxyribonucleotide probes corre-
sponding to selected fragments of cDNAs of
PAP and PSA were used to study the effect of
steroid hormones and growth factors on
mRNA levels of these two prostate specific
proteins in benign hyperplastic prostate tis-
sue. Two of them: the 29-mer 5-TGG GAC
TTC GGT CTC CAT GCC GAA ACA CC-3 and
31-mer 5-GGG ATC ACA GGG CCA ACC
AGC TCA GCA AAC C-3, were identical to
the fragments of the sense strand of PAP
cDNA between positions 143–171 and
1087–1117, respectively (Vihko et al., 1988)
and had been already successfully used
(Duliñska et al., 1997). The next two, the 31
mer 5-CTT GGT CAC CTT CTG AGG NGT
GAA CTT GCG C-3 and 30 mer 5-CAC CTG
CCA GGG TTG GGA ATG CTT CTC GCA-3 —
were complementary to the fragments of the
sense strand of PSA cDNA between positions
552–582, and 91–120, respectively (Watt et
al., 1986). All the probes were labeled with 32P
and the preparations of the highest specific
activities (1 Ci/ng) were used to search the
respective mRNAs in the prostate tissues
studied and epithelial secretory cells derived
from them. Such labeling allowed for 1–5 day
exposure of the hybridized samples.
The analysis of total RNA samples isolated
from a large number of benign hyperplastic
prostate tissues (n = 12) indicated the pres-
ence of mRNAs for PAP (about 3.3 kb) and
PSA (about 1.6 kb). The sizes of mRNA for
these prostate specific proteins remain in
agreement with those reported previously
(Duliñska et al., 1997). The intensity of both
PAP and PSA mRNA bands depended on the
composition of the medium in which slices of
tissue were incubated (up to 24 h) prior to
RNA isolation. Clearly the addition of DHT, E,
bFGF and EGF to the steroid free RPMI 1640
medium (SF) increased the intensities of
bands representing both mRNAs (Fig 1). In
each case they depended on the concentration
of the steroid hormone and/or growth factor
added as well as on time of incubation of BPH
tissue slices in the medium (not shown).
DHT has been recognized as the most impor-
tant factor that affects the metabolism of pros-
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tate tissue (Duliñska et al., 1997; Kim et al.,
1996). Our analysis of over 40 tissue samples
from different BPH donors indicated unani-
mous reproducibility and statistical signifi-
cance (P < 0.001) of the observed effect (Ta-
ble 1).
We were able to show that PAP mRNA level
increased significantly during the first few
hours of incubation and reached the highest
value — 3-fold increase of the initial level — af-
ter 3–5 h. The most profound effect — not less
than 6-fold increase of PAP mRNA level in
Vol. 49 Prostate-specific proteins in BPH 361
Figure 1. Northern blot analysis of PAP (A) and PSA (B) mRNAs in total RNA isolated from human pros-
tatic tissue.
A. 1. SF, 2. DHT (10
–11
M), 3. DHT (10
–11
M) + bFGF (10 ng/ml), 4. DHT (10
–11
M) + EGF (10 ng/ml), 5. DHT (10
–11
M) + E (10
–7
M). B. 1. SF, 2. DHT (10
–11
M), 3. DHT (10
–11
M) + bFGF (10 ng/ml), 4. DHT (10
–11
M) + EGF (10
ng/ml), 5. DHT (10
–11
M) + E (10
–7
M). Total RNA (25 g) from benign hyperplastic tissue was fractionated by elec-
trophoresis (1.2%) and afterwards hybridized to
32
P-labeled specific oligonucleotide probes for PAP (A) or PSA (B)
mRNA.
Table 1. The effect of different concentrations of DHT (10
–7
M/10
–11
M) on the level of PAP mRNA
in benign hyperplastic prostate tissue (n = 42).
Tissue slices were incubated for 1, 2, 3, 4, 5 and 24 h (37C, 5% CO2) with appropriate factors added to RPMI
1640 serum free medium (SF). The analysis of PAP mRNA was done as described under Materials and
Methods.
Level of PAP mRNA (percentage of initial value)
Time 0 h 1 h 3 h 4 h 5 h 24 h
DHT concn. (M) mean mean S.D. mean S.D. mean S.D. mean S.D. mean S.D.
SF (no DHT) 100.0 86.50 14.50 68.81 10.81 48.60 14.77 44.52 12.92 18.33 9.35
10
–11
100.0 175.80 14.80 252.00 25.20 330.0 33.0 302.50 38.00 259.50 40.00
10
–10
100.0 165.00 18.10 201.20 20.20 298.00 36.15 289.50 31.20 259.85 33.00
10
–9
100.0 165.00 24.10 179.00 27.00 211.50 23.00 202.65 29.20 169.00 22.25
2  10
–8
100.0 153.20 23.15 172.00 17.00 198.80 17.00 203.50 27.00 174.00 19.20
10
–7
100.0 122.00 17.20 101.00 11.00 79.00 12.00 67.00 11.00 55.00 16.00
comparison with its level in the sample of the
same tissue incubated in parallel without DHT
— was observed at 4th hour of incubation for
10–11M final concentration of DHT (Fig. 2).
Based on the results of studies on DHT effect
on PAP mRNA level in BPH tissue slices the
choice of 4 h incubation time was made to
study short time effects of the remaining fac-
tors, such as E, EGF and bFGF. The addition
of E, EGF or bFGF to the incubation medium
caused approximately 2-fold increase of PAP
mRNA level (Fig. 3). Supplementation of a
DHT containing incubation medium with any
of those factors led in each case to a statisti-
cally significant increase (P < 0.005) of PAP
mRNA. The highest increase was observed for
bFGF/DHT (Fig. 3). Analogous experiments
were carried out on cultured cells released
from BPH tissue slices. The cells showed PAP
activity as was confirmed by enzyme chemical
and histochemical assays (not shown). The
same effects of steroid hormones and growth
factors as those for tissue slices were ob-
served (Fig. 4).
Parallel analysis of BPH tissue slices and
cells derived from them for PSA mRNA
showed quite similar effects when DHT, E,
bFGF and EGF were used in the medium as
the only factor or when DHT and one of the re-
maining factors were both present (Fig. 5 and
Fig. 6). Again, DHT caused a 3-fold increase of
the PSA mRNA. However, this time the high-
362 J. Duliñska and others 2002
0%
50%
100%
150%
200%
250%
300%
350%
0h 1h 3h 4h 5h 24htime
P
A
P
m
R
N
A
(%
o
f
in
it
ia
l
v
a
lu
e
)
SF DHT 10-7 DHT2x10-8
DHT10-9 DHT10-10 DHT10-11
Figure 2. The effect of different con-
centrations of DHT (10
–7
–10
–11
M) on
the level of PAP mRNA in benign
hyperplastic prostate tissue (n = 42).
Presented are the mean values of mRNA
levels (included in Table I) detected at vari-
ous times of incubation.
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Figure 3. The effect of steroid hor-
mones (DHT 10
–11
M, E 10
–7
M) or
growth factors (bFGF 10 ng/ml, EGF 10
ng/ml) on the level of PAP mRNA in be-
nign hyperplastic prostate tissue (n =
12).
Tissue slices were in each case incubated
with appropriate factor(s) for 4 h (37C, 5%
CO2) added to RPMI 1640 serum free me-
dium (SF). The analysis of PAP mRNA was
done as described under Materials and
Methods. The PAP mRNA level was ex-
pressed as percentage of its initial level.
*Significantly higher than control (P <
0.05). **Significantly higher than control (P
< 0.005).
est (10-fold) and most significant (P < 0.001)
increase of PSA mRNA level was observed for
tissue samples incubated in medium contain-
ing both DHT and EGF (Fig. 5) rather than
DHT and bFGF as it was in the case of PAP
mRNA level (Fig. 3).
The addition of E to incubation medium ei-
ther in the case of tissue slices or cultured
cells derived from the same BPH tissue led to
a 2-fold increase of PAP as well as PSA mRNA
levels in comparison with the 5–6 fold in-
crease if DHT was used as the only factor
(Figs. 4 and 6). Supplementation of a DHT
containing medium with E did not bring about
any change in PAP mRNA level (Fig. 4) and
significant increase (P < 0.001) in the case of
PSA mRNA level (Fig. 6). Thus E by itself did
not seem to affect either PAP or PSA mRNA
levels as much as DHT did in short term incu-
bation of tissue slices or cells derived from
them. Perhaps it nonspecifically sustains
transcription from both the PAP and PSA
genes and/or increases stability of the respec-
tive mRNAs. E has a different effect on PAP
and PSA mRNA levels if DHT is also present
in the medium (Figs. 4 and 6).
DISCUSSION
There is no single experimental model that
could be used for studies of BPH in humans.
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Figure 4. Comparison of the effect of E
(10
–7
M), E/DHT (10
–7
M/10
–11
M),
DHT (10
–11
M) and/or bFGF (10 ng/ml)
on the level of PAP mRNA in BPH tis-
sue slices and cultured cells derived
from them (n = 12).
The PAP mRNA level was expressed as per-
centage of its initial level. *Significantly
higher than control (P < 0 .05). **Signifi-
cantly higher than control (P < 0.001).
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Figure 5. The effect of steroid hor-
mones (DHT 10
–11
M, E 10
–7
M) or
growth factors (bFGF 10 ng/ml, EGF
10 ng/ml) on the level of PSA mRNA in
benign hyperplastic prostate tissue (n =
12).
Tissue slices were incubated for 4 h (37C,
5% CO2) with appropriate factor(s) added to
RPMI 1640 serum free medium (SF). The
analysis of PSA mRNA was done as de-
scribed under Materials and Methods. The
PSA mRNA level was expressed as percent-
age of its initial level. *Significantly higher
than control value (P < 0.05). **Signifi-
cantly higher than control value (P <
0.001).

We recently successfully studied the effect of
DHT on mRNA level of PAP in BPH using tis-
sue slices kept in culture conditions for up to
72 h (Duliñska et al., 1997). DHT, EGF and
bFGF affect the proliferation of prostate epi-
thelial as well as stromal cells (Kim et al.,
1996; Tenniswood et al., 1990). To avoid the
interference of the proliferative effect short-
term cultures seem to offer an advantage and
allow one to observe the influence of a steroid
hormone or GF on the expression of genes of
interest minimizing the effect of cell growth
and proliferation.
Using that model we recently reported that
DHT is an important factor sustaining the ex-
pression of PAP mRNA in BPH (Duliñska et
al., 1997). The present study clearly indicated
DHT as a major factor that affects the expres-
sion of not only PAP but also the PSA gene
and/or the stability of the respective mRNAs
in benign hyperplastic prostate tissue. In a
short time scale experiments the differences
between the mRNA levels for both these pros-
tate-specific proteins — isolated from tissue
slices or cells derived from them — incubated
in a medium supplemented with DHT and
without the hormone, were significant.
Bearing in mind that the prostate is an an-
drogen-responsive organ (Isaacs, 1994) it is
not surprising that DHT, a major androgen of
prostate epithelial and stromal cells so seri-
ously affects the level of the mRNAs of PAP
and PSA, the most characteristic proteins of
this gland. The results obtained from mea-
surements of PAP and PSA serum levels in
cancer patients after endocrine therapy sug-
gested a similar androgen dependency for the
regulation of expression of both these genes
(Pamies & Crawford, 1996). In contrast, in
LNCaP cell line the expression of PAP at the
mRNA level was decreased, while that of PSA
remained essentially the same upon DHT
treatment (Henttu et al., 1992). The dimin-
ished expression of PAP in high passages of
LNCaP cells might indicate that adrogenic
transcriptional modulation of PAP expression
changes upon passages. It is also possible that
the decreased expression of PAP could have
been due to de-differentiation of LNCaP cells
following in vitro passages, since PAP is the
major prostate-epithelium differentiation an-
tigen (Lin et al., 1998). In ALVA-31 prostate
carcinoma cells the decrease in the expression
of PAP leading to its final loss was consistent
throughout continued passages of the cells in-
dicating the possible biological significance of
low PAP expression as a marker of a high
grade/stage tumors (Garcia-Arenas et al.,
1995). If it is the case, our observation of the
stimulatory effect of DHT on PAP mRNA level
reflects the differences between the biological
status of BPH tissue and cancer cells. The in-
crease of PSA mRNA level in response to DHT
stimulation suggests that in BPH tissue both
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Figure 6. Comparison of the effect of E
(10
–7
M), E/DHT (10
–7
M/10
–11
M), DHT
(10
–11
M) and/or EGF 10ng/ml on the
level of PSA mRNA in BPH tissue slices
and derived from them cultured cells
(n = 12).
The PSA mRNA level was expressed as per-
centage of its initial level. *Significantly
higher than control value (P < 0.05). **Sig-
nificantly higher than control value (P <
0.001).
genes are similarly controlled via androgens
and that both genes contain androgen respon-
sive elements. This corresponds well with the
results obtained by Nevalainen et al. (1993)
who have shown that androgens increased the
level of PSA mRNA by activating transcrip-
tion of the PSA gene containing an androgen
responsive element in the promoter region.
Although the mechanisms leading to the de-
velopment of human BPH are still largely un-
known, there are several findings that suggest
an involvement of bFGF in the pathogenesis.
bFGF is expressed in hyperplastic prostates,
where its concentration is as much as 2 or 3
times higher than in the normal prostate
(Mydlo et al., 1988). bFGF is also well known
as a growth-stimulating factor for prostatic
stromal and epithelial cells in vitro (Geller,
1990; Sherwood et al., 1992). Finasteride — a
potent and specific inhibitor of type II
5--reductase — reduces circulating and
intraprostatic DHT levels (McConnell et al.,
1992). The reduction of bFGF expression
caused by finasteride in BPH specimens con-
firms the importance of the role of bFGF in
the development of this condition. Reduced
level of DHT could negatively affect bFGF
transcription. Several studies support the
view on a direct effect of androgens on bFGF
gene regulation at the transcription level.
Saez et al. (1999) conclude that finasteride
could act as a negative regulator of bFGF ex-
pression and thus counteract the role of bFGF
in the development of BPH. Our results show-
ing an undoubtedly synergistic effect of bFGF
and DHT especially on the expression and/or
stability of PAP mRNA reflect the different
and independent modes of action of this
growth factor on prostatic cell proliferation
and on the expression on the PAP gene or its
mRNA stability.
Many studies focused on the co-regulation of
the androgens and growth factors in prostatic
cancer growth. Frydenberg et al. (1991) re-
ported that EGF might also mediate the pros-
tatic growth influenced by the androgenic mi-
lieu. The nature of the interactions between
androgens and EGF in prostate cancer re-
mains unclear although according to some au-
thors androgens do not regulate the EGF-re-
ceptor expression, while, for most of them —
they do (Frydenberg et al., 1991; Shuurmans
et al., 1991). Janssen et al. (1995) reported
that DHT and EGF have a synergistic or an
antagonistic effect on each other in respect to
the cell kinetics of three prostate cancer cell
lines — two androgen-insensitive PC-3 and
DU-145 and the androgen-sensitive LNCaP
model.
A recently formulated hypothesis pointed to
DHT as an important factor that through de-
creased expression and/or inactivation of
PAP causes uncontrolled stimulation of the
EGF signal pathway and, in consequence,
prostate cell proliferation (Lin et al., 1998;
Zelivianski et al., 2000). This supports the
view that sex steroids act on cell proliferation
mainly indirectly, modulating the production
and/or activity of growth factors. Our studies
indicated a strongly synergistic effect of EGF
and DHT on the expression and/or stability of
PSA mRNA. This contradictory observation —
in light of the results of Meng et al. (2000) —
suggests different mechanisms of regulation
of expression of important prostate tissue
genes in BPH and in prostatic cancer cells. It
also strengthens the view that PSA and PAP
genes in BPH are expressed via various
though partially analogous (effect of DHT)
mechanisms.
The hypothesis of a primary stromal abnor-
mality in BPH is supported by the findings of
an increased activity of 5--reductase and of
the high content of estrogens and their recep-
tors in the stroma. In human BPH tissue
estradiol, acting in association with sex hor-
mone binding globulin (SHBG) produces an
8-fold increase in the cellular cAMP levels, pri-
marily in the stroma (Rosner et al., 1999). The
effect is mediated by DHT, which restrains
the binding of estradiol to SHBG. It is also
possible that estrogens may increase the re-
sponsiveness of human BPH stromal cells to
androgens by up-regulating AR levels. The
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binding of estradiol or progesterone to ARs
not only increased the proliferation of
LNCaP, but also elicited effects on the
mRNAs originating from androgen-regulated
genes that were compared to those elicited by
the androgenic steroids. The level of PAP and
hAR mRNAs decreased in LNCaP cells
treated with estradiol or progesterone and the
synthetic androgen R1881 as well as in cells
treated with R1881 alone. On the other hand,
estradiol increased the level of PSA mRNA.
Thus our results on the effect of estradiol on
PAP and PSA mRNA expression and stability,
similarly as in the case of bFGF and EGF,
showed different modulation by E of PAP and
PSA gene expression and/or their mRNA sta-
bility in BPH and in prostate cancer cells.
Further studies are required to assess what
regulatory mechanisms that include both
DHT and bFGF as well as EGF are involved in
the control of the expression of the PAP and
PSA genes in BPH.
The authors wish to thank Professor Jerzy
Stachura (Department of Pathomorphology,
Collegium Medicum, Jagiellonian University,
Kraków) for histopathological verification of
the tissues studied and Professor Jan Litwin
(Department of Histology, Collegium Medicum,
Jagiellonian University, Kraków) for valuable
discussion concerning cell culture.
R E F E R E N C E S
Barka T, Andersson PJ. (1962) Histochemical
methods for acid phosphatase using
pararosanilin as coupler. J Histochem
Cytochem.; 10: 741–53.
Cooper AC, Foti A. (1974) A radioimmunoassay
for prostatic acid phosphatase. Investig Urol.;
12: 98–102.
Daniels WW. (1999) Biostatistics: a fundation for
analysis in the health science, New York, Wiley
J and Sons.
Diamandis EP, Yu H. (1995) New biological func-
tions of prostate-specific antigen? J Clin
Endocrinol Metab.; 80: 1515–7.
Duliñska J, Laidler P, Ostrowski WS, Mrozicki
S, Ga³ka M. (1997) The effect of
dihydrotestosterone on transcription of pros-
tatic acid phosphatase mRNA in human
hyperplastic gland. Acta Biochim Polon.; 44:
751–8.
Farnsworth WE. (1996) Roles of estrogen and
SHBG in prostate physiology. Prostate.; 28:
17–23.
Frydenberg M, Foo TM, Jones AS, Grace J,
Hensley WJ, Rogers J, Pearson BS,
Raghavan D. (1991) Benign prostatic hyper-
plasia — video image analysis and its relation-
ship to androgen and epidermal growth fac-
tor receptor expression. J Urol.; 146: 872–6.
Garcia-Arenas R, Lin FF, Lin D, Jin LP, Shih
CC-Y, Chang C, Lin MF. (1995) The expres-
sion of prostate acid phosphatase is
transcriptionally regulated in human pros-
tate carcinoma cells. Mol Cell Biol.; 111:
29–37.
Geller J. (1990) Effect of finasteride, a
5-reductase inhibitor on prostate tissue an-
drogens and prostate-specific antigen. J Clin
Endocrinol Metab.; 71: 1552–5.
Guenette RS, Tenniswood M. (1994) The role of
growth factors in the suppression of active
cell death in the prostate: an hypothesis.
Biochem Cell Biol.; 72: 553–9.
Henttu P, Vihko P. (1992) Steroids inversely af-
fect the biosynthesis and secretion of human
prostatic acid phosphatase and prostate-
specific antigen in the LNCaP cell line. J Ste-
roid Biochem Mol Biol.; 41: 349–60.
Henttu P, Liao S, Vihko P. (1992) Androgens
up-regulate the human prostate-specific anti-
gen messenger ribonucleic acid (mRNA), but
down-regulate the prostatic acid phosphatase
mRNA in the LNCaP cell line. Endocrinology;
130: 766–72.
Heston WD. (1996) Significance of pros-
tate-specific membrane antigen (PSMA)
a neurocarboxypeptidase and membrane fo-
late hydrolase. Urology A.; 35: 400–7.
366 J. Duliñska and others 2002
Isaacs JT. (1994) Role of androgens in prostatic
cancer. Vitamins Horm.; 49: 433–502.
Janssen T, Kiss R, Dedecker R, Petein M,
Pasteels JL, Schulman C. (1995) Influence of
dihydrotestosterone, epidermal growth fac-
tor, and basic fibroblast growth factor on the
cell kinetics of the PC3, DU 145, and LNCaP
prostatic cancer cell lines: relationships with
DNA ploidy level. Prostate.; 27: 277–86.
Kim IY, Kim JH, Zelner DJ, Ahn HJ, Sensibar
JA, Lee Ch. (1996) Transforming growth fac-
tor-1 is a mediator of anrdogen-regulated
growth arrest in an androgen-responsive
prostatic cancer cell line, LNCaP. Endocrinol-
ogy.; 137: 991–9.
Krieg M, Bartsch W, Herzer S, Becker H, Voigt
KD. (1977) Quantification of androgen bind-
ing, androgen tissue levels, and sex hor-
mone-binding globulin in prostate, muscle
and plasma of patients with benign prostatic
hypertrophy Acta Endocrinol (Copenh).; 86:
200–15.
Lin MF, Garcia-Arenas R, Chao Ych, Lai MMC,
Patel PC, Xia XZ. (1993) Regulation of pros-
tatic acid phosphatase expression and secre-
tion by androgen in LNCaP prostate carci-
noma. Arch Biochem Biophys.; 300: 384–90.
Lin MF, Meng TC, Rao PS, Chang C, Schonthal
AH, Lin FF. (1998) Expression of human
prostatic acid phosphatase correlates with
androgen-stimulated cell proliferation in
prostate cancer cell lines. J Biol Chem.; 273:
5939–47.
McConnell JD, Wilson JD, George FW, Geller J,
Papppas F, Stoner E. (1992) Finasteride, an
inhibitor of 5-reductase, suppresses pros-
tatic dihydrotestosterone in men with benign
prostatic hyperplasia. J Clin Endocrinol
Metab.; 74: 505–8.
Meng TC, Lin MF. (1998) Tyrosine
phosphorylation of c-ErbB-2 is regulated by
the cellular form of prostatic acid
phosphatase in human prostate cancer cells J
Biol Chem.; 273: 22096–104.
Meng TC, Lee MS, Lin MF. (2000) Interaction
between protein tyrosine phosphatase and
protein tyrosine kinase is involved in andro-
gen-promoted growth oh human prostate can-
cer cells. Oncogene.; 19: 2664–77.
Murtha P, Tindall DC, Young CY. (1993) Andro-
gen induction of a human prostate-specific
kallikrein, hKLK2: characterization of an an-
drogen response element in the 5 promoter
region of the gene. Biochemistry.; 32:
6459–6464.
Mydlo J, Michaeli, J, Heston, W, Fair W. (1988)
Expression of basic fibroblastic growth factor
mRNA in benign prostatic hyperplasia and
prostatic carcinoma. Prostate; 13: 241–7.
Nevalainen MT, Harkonen PL, Valve EM, Ping
W, Nurmi W, Martikainen PM. (1993) Hor-
mone regulation of human prostate in organ
culture. Cancer Res.; 53: 5199–207.
Ostrowski W, Tsugita A. (1961) Purification of
acid phosphomonoesterase from human pros-
tate gland. Arch Biochem.; 94: 68–73.
Pamies RJ, Crawford DR. (1996) Tumor mark-
ers. An update. Med Clin North Am.; 80:
185–99.
Peterziel H, Mink S, Schonert A, Becker M,
Klocker H, Cato ACB. (1999) Rapid signaling
by androgen receptor in prostate cancer
cells. Oncogene.; 18: 6322–9.
Pilarsky CP, Schmidt U, Eissrich C, Stade J,
Froschermaier SE, Haase M, Faller G,
Kirchner TW, Wirth MP. (1998) Expression
of the extracellular matrix signalling mole-
cule Cyr61 is downregulated in prostate can-
cer. Prostate.; 36: 85–91.
Robert M, Gibbs B.F, Jacobsen T, Gangon C.
(1995) Characterization of prostate specific
antigen proteolitic activity on its major physi-
ological substrate, the sperm motility inhibi-
tor precursor/semenogelin I. Biochemistry.;
36: 811–6.
Rosner W, Hryb DJ, Khan MS, Nakhla AM,
Romas NA. (1999) Sex hormone-binding glob-
ulin mediates steroid hormone signal
transduction at the plasma membrane. J Ste-
roid Biochem Molec Biol.; 69: 481–5.
Saez C, Gonzalez-Baena AC, Japon MA, Giraldez
J, Segura DI, Rodriguez-Vallejo JM, Gonza-
lez-Esteban J, Miranda G, Torrubia F. (1999)
Expression of basic fibroblast growth factor
Vol. 49 Prostate-specific proteins in BPH 367
and its receptors FGFR1 and FGFR2 in hu-
man benign prostatic hyperplasia treated
with finasteride. Prostate.; 40: 83–8.
Sherwood ER, Fong CJ, Lee C, Koz³owski JM.
(1992) Basic fibroblast growth factor: a po-
tential mediator of stromal growth in the hu-
man prostate. Endocrinology.; 130: 2955–63.
Shuurmans ALG, Bolt J, Veldscholte J, Mulder
E. (1991) Regulation of growth factors and
steroid hormones. J Steroid Biochem Mol
Biol.; 40: 193–7.
Solin T, Kontturi M, Pohlmann R, Vihko P.
(1990) Gene expression and prostate specific-
ity of human prostatic acid phosphatase
(PAP): evolution by RNA blot analyses
Biochim Biophys Acta.; 1048: 72–7.
Tenniswood MP, Montpetit NL, Leger JG, Wong
P, Pineault JM, Rouleau M. (1990) Epithe-
lial-stromal interactions and cell death in the
prostate. In The prostate as an endocrine
gland. Fornsworh WE, Ablin RJ. eds, pp
187–207. CRC Press, Boca Raton, Fla.
Van Helden PD, Wiid IJF, Hoal-van Helden EG,
Bey E, Cohen, R. (1994) Detection by DNA
fingerprinting of somatic changes during the
establishment of a new prostate cell line Br J
Cancer.; 70: 195–8.
Vihko P, Virkkunen P, Henttu P, Roiko K, Solin
T, Huhtala ML. (1988) Molecular cloning and
sequence analysis of cDNA encoding human
prostatic acid phosphatase. FEBS Lett.; 236:
275–81.
Watt KWT, Lee PJ, M’Timkulu T, Chan WP,
Loor R. (1986) Human prostate-specific anti-
gen: structural and functional similarity with
serine proteases. Proc Natl Acad Sci U S A.;
83: 3166–70.
Zelivianski S, Larson C, Seberger J, Taylor R,
Lin MF. (2000) Expression of human pros-
tatic acid phosphatase gene is regulated by
upstream negative and positive elements
Biochim Biophys Acta.; 1491: 123–32.
368 J. Duliñska and others 2002
